Tema Etfs LLC Has $2.19 Million Position in Immunome, Inc. $IMNM

Tema Etfs LLC cut its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 37.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 102,055 shares of the company’s stock after selling 60,131 shares during the quarter. Tema Etfs LLC owned 0.11% of Immunome worth $2,192,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Assetmark Inc. acquired a new stake in shares of Immunome in the third quarter valued at approximately $39,000. BIT Capital GmbH acquired a new stake in shares of Immunome in the third quarter valued at about $69,000. BNP Paribas Financial Markets boosted its position in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Immunome during the 3rd quarter worth approximately $76,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after buying an additional 3,802 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Buying and Selling

In other news, Director Philip Wagenheim sold 36,800 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $20.47, for a total value of $753,296.00. Following the completion of the transaction, the director directly owned 369,347 shares in the company, valued at approximately $7,560,533.09. The trade was a 9.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.69% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research note on Thursday, January 15th. HC Wainwright started coverage on Immunome in a research report on Thursday, February 12th. They set a “buy” rating and a $40.00 price target on the stock. Leerink Partners set a $40.00 price objective on Immunome in a research report on Monday, December 15th. Craig Hallum boosted their target price on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, Stephens reduced their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.45.

Immunome Price Performance

Shares of NASDAQ IMNM opened at $21.84 on Friday. The business has a fifty day moving average price of $22.42 and a two-hundred day moving average price of $19.13. The stock has a market capitalization of $2.47 billion, a PE ratio of -9.02 and a beta of 2.13. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $27.65.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). On average, equities analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.